These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34551970)

  • 1. Repurposing Vandetanib plus Everolimus for the Treatment of
    Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
    Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK2 inhibitors display beneficial effects in preclinical models of
    Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
    Commun Biol; 2019; 2():156. PubMed ID: 31098401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
    Broniscer A; Baker SD; Wetmore C; Pai Panandiker AS; Huang J; Davidoff AM; Onar-Thomas A; Panetta JC; Chin TK; Merchant TE; Baker JN; Kaste SC; Gajjar A; Stewart CF
    Clin Cancer Res; 2013 Jun; 19(11):3050-8. PubMed ID: 23536435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
    Hoeman CM; Cordero FJ; Hu G; Misuraca K; Romero MM; Cardona HJ; Nazarian J; Hashizume R; McLendon R; Yu P; Procissi D; Gadd S; Becher OJ
    Nat Commun; 2019 Mar; 10(1):1023. PubMed ID: 30833574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
    Patay Z; Merchant TE; Nguyen R; Pierson CR; Onar-Thomas A; Broniscer A
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1295-1305. PubMed ID: 29165288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
    Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
    Thomas L; Smith N; Saunders D; Zalles M; Gulej R; Lerner M; Fung KM; Carcaboso AM; Towner RA
    J Transl Med; 2020 Nov; 18(1):424. PubMed ID: 33168005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
    Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A
    J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
    Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
    Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
    Han HJ; Jain P; Resnick AC
    Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
    Sedlacik J; Winchell A; Kocak M; Loeffler RB; Broniscer A; Hillenbrand CM
    AJNR Am J Neuroradiol; 2013 Jul; 34(7):1450-5. PubMed ID: 23436052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
    Fortin J; Tian R; Zarrabi I; Hill G; Williams E; Sanchez-Duffhues G; Thorikay M; Ramachandran P; Siddaway R; Wong JF; Wu A; Apuzzo LN; Haight J; You-Ten A; Snow BE; Wakeham A; Goldhamer DJ; Schramek D; Bullock AN; Dijke PT; Hawkins C; Mak TW
    Cancer Cell; 2020 Mar; 37(3):308-323.e12. PubMed ID: 32142668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
    Veringa SJ; Biesmans D; van Vuurden DG; Jansen MH; Wedekind LE; Horsman I; Wesseling P; Vandertop WP; Noske DP; Kaspers GJ; Hulleman E
    PLoS One; 2013; 8(4):e61512. PubMed ID: 23637844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.